These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 19260351)

  • 1. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.
    Katsube T; Yano Y; Yamano Y; Munekage T; Kuroda N; Takano M
    J Pharm Sci; 2008 Sep; 97(9):4108-17. PubMed ID: 18314887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of clinical bacteriological efficacy of oral antibiotics using a mechanism-based pharmacokinetic-pharmacodynamics modeling.
    Matsumoto K; Sugano T; Sato N; Ida T; Shibasaki S
    Jpn J Antibiot; 2014 Feb; 67(1):33-47. PubMed ID: 24809207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
    Katsube T; Yamano Y; Yano Y
    J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Takahashi H
    Jpn J Antibiot; 2004 Dec; 57(6):465-74. PubMed ID: 15747584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-response studies and modelling of the pharmacodynamics of linezolid: Staphylococcus aureus versus Enterococcus faecium.
    Scheerans C; Wicha SG; Michael J; Derendorf H; Kloft C
    Int J Antimicrob Agents; 2015 Jan; 45(1):54-60. PubMed ID: 25455852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
    Preston SL
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
    Budha NR; Lee RB; Hurdle JG; Lee RE; Meibohm B
    Tuberculosis (Edinb); 2009 Sep; 89(5):378-85. PubMed ID: 19748318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.
    Sy SK; Zhuang L; Derendorf H
    Expert Opin Drug Metab Toxicol; 2016; 12(1):93-114. PubMed ID: 26652832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal adaptive control of pharmacodynamic effects with aminoglycoside antibiotics: a required approach for the future.
    Garraffo R
    Int J Biomed Comput; 1994 Jun; 36(1-2):43-57. PubMed ID: 7927859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis on the sensitivity to beta-lactam antibiotics of respiratory-infectious isolates on the second survey on the sensitivity of isolates conducted by the Japanese Society of Chemotherapy in 2007--concerning the aspect of PK/PD break points].
    Niki Y; Kohno S; Watanabe A; Aoki N
    Jpn J Antibiot; 2009 Jun; 62(3):203-13. PubMed ID: 19882981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How predictive is PK/PD for antibacterial agents?
    Frimodt-Møller N
    Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.